Clinical Trial Update: Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line Vebreltinib plus PLB1004 in patients with EGFR-mutant, MET-positive locally advanced or metastatic Non-Small-Cell Lung Cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PLB1004
• Vebreltinib (vebreltinib)

Snippet

Sponsor: Avistone Biotechnology Co., Ltd. | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: RECRUITING